NASDAQ:DSGN
Design Therapeutics, Inc.
Design Therapeutics, Inc.'s revenue was $0 in fiscal 2025. Free cash flow was −$54.6M, and the diluted share count rose 1.3%.Summary generated from Design Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−30.7%
Debt / equityn/a
Free cash flow−$54.6M
FCF marginn/a
Share count change+1.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 0 | 0 |
| Operating income | −36 | −68 | −78 | −62 | −79 |
| Net income | −36 | −63 | −67 | −50 | −70 |
| Free cash flow | −31 | −52 | −59 | −43 | −55 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 3, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026 - 4Insider transaction report
Jun 11, 2026 - 4Insider transaction report
Jun 11, 2026 - 8-KResults of a shareholder vote
Jun 11, 2026 - 8-KOther events
May 18, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 28, 2026 - 8-KResults of operations and financial condition
Apr 28, 2026